Literature DB >> 17192761

Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour.

Lawrence F Blob1, Melvin Sharoky, Bryan J Campbell, Eva M Kemper, Michelle Gilmor Gilmor, Chad M VanDenberg, Albert J Azzaro.   

Abstract

BACKGROUND: Monoamine oxidase inhibitors are well recognized as effective antidepressant agents but are rarely used due, in part, to the risk of hypertensive crisis following the ingestion of foods high in tyramine ("cheese reaction"). A selegiline transdermal system (STS) was developed to provide antidepressant concentrations of selegiline in the brain, while preserving the gastrointestinal monoamine oxidase A (MAO-A) barrier. The present study was conducted to determine the effect of the STS 6 mg/24 hour on cardiovascular safety following the ingestion of approximately 400 mg of tyramine consumed as a component of aged cheeses.
METHODS: In this open-label, single-center phase I study, cardiovascular vital signs were recorded following tyramine challenges during placebo and STS 6 mg/24 hr treatment. Subjects were observed for clinical signs and symptoms of a pressor response and/or potential hypertensive crisis during and following the challenges.
RESULTS: Ingestion of tyramine-enriched meals following 13 consecutive days of treatment with the STS 6 mg/24 hr (pharmacokinetic steady-state) produced no clinically significant changes in cardiovascular vital signs in 12 healthy adult male subjects. No evidence of a tyramine pressor effect on systolic blood pressure or evidence of hypertensive crisis occurred during the STS treatment.
CONCLUSION: These results suggest that STS 6 mg/24 hr may be administered without concern for dietary tyramine consumption.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17192761     DOI: 10.1017/s1092852900020496

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  5 in total

1.  An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?

Authors:  Ramadhan Oruch; Anders Lund; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2010-01-27

Review 2.  Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features.

Authors:  Alberto Mazza; Roberta Ravenni; Angelo Antonini; Edoardo Casiglia; Domenico Rubello; Paolo Pauletto
Journal:  Neurol Sci       Date:  2012-11-30       Impact factor: 3.307

Review 3.  Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.

Authors:  John P M Finberg; Jose M Rabey
Journal:  Front Pharmacol       Date:  2016-10-18       Impact factor: 5.810

Review 4.  Selegiline: a molecule with innovative potential.

Authors:  Tamás Tábi; László Vécsei; Moussa B Youdim; Peter Riederer; Éva Szökő
Journal:  J Neural Transm (Vienna)       Date:  2019-09-27       Impact factor: 3.575

5.  Transdermal selegiline for the treatment of major depressive disorder.

Authors:  Kelly C Lee; Jack J Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.